Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation

• Ngā kaituhi matua: Olivier Corbeil (Author), Anne-Marie Essiambre (Author), Laurent Béchard (Author), Audrey-Anne Roy (Author), Maxime Huot-Lavoie (Author), Sébastien Brodeur (Author), Ranjith Chandrasena (Author), Chantale Thériault (Author), Candice Crocker (Author), Jean-Pierre Melun (Author), Phil Tibbo (Author), Marie-France Demers (Author), Marc-André Roy (Author)
• Hōputu: Pukapuka
• I whakaputaina: SAGE Publishing, 2022-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background: Non-adherence to antipsychotics in schizophrenia is associated with an increased risk of psychotic relapse and hospitalization, a risk that is reduced with the use of long-acting injectable (LAI) antipsychotics. Randomized clinical trials (RCTs) have demonstrated the efficacy of paliperi...